Literature DB >> 8250975

Participation of the CYP2D subfamily in lidocaine 3-hydroxylation and formation of a reactive metabolite covalently bound to liver microsomal protein in rats.

Y Masubuchi1, S Umeda, S Igarashi, S Fujita, S Narimatsu, T Suzuki.   

Abstract

Lidocaine metabolism was investigated in rat liver microsomes and in a reconstituted system containing P450BTL, a cytochrome (P450) isozyme belonging to the CYP2D subfamily (Suzuki et al., Drug Metab Dispos 20: 367-373, 1992). P450BTL biotransformed lidocaine into 3-hydroxylidocaine (3-OH-LID) but not monoethylglycinexylidide and 2-methylhydroxylidocaine, in the reconstituted system including NADPH-P450 reductase and dilauroylphosphatidylcholine. An antibody against P450BTL inhibited microsomal lidocaine 3-hydroxylase activity by 97%. Thus, P450BTL and/or its immunorelated P450 isozyme(s) belonging to the CYP2D subfamily appear to be involved in lidocaine 3-hydroxylation. Furthermore, the antibody also suppressed the amounts of a lidocaine metabolite(s) bound to microsomal protein. These results suggest that the CYP2D subfamily biotransformed lidocaine into 3-OH-LID via an epoxy intermediate, which binds to microsomal macromolecules.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8250975     DOI: 10.1016/0006-2952(93)90596-o

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  2 in total

Review 1.  Mechanisms of drug-induced delayed-type hypersensitivity reactions in the skin.

Authors:  Sanjoy Roychowdhury; Craig K Svensson
Journal:  AAPS J       Date:  2005-12-09       Impact factor: 4.009

2.  Stress-induced lidocaine modification in serum and tissues.

Authors:  T Saranteas; C Tesseromatis; A Potamianou; C Mourouzis; D Varonos
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Oct-Dec       Impact factor: 2.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.